Pneumococcal Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028

Pneumococcal Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028



Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk groups, such as young children and the elderly, where the immune system is more vulnerable.

Theepidemiologists utilized comprehensive, country-specific pneumococcal vaccination rate data and IPD diagnosed incidence rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth epidemiological analysis and forecast. Moreover, Theepidemiologists provide detailed dose- and age-specific pneumococcal vaccination rates that are dependent on the routine immunization requirements of each market.

Theepidemiologists forecast that the pneumococcal vaccinated pediatric population in the 5GM will increase from 20,087,973 children vaccinated in 2018 to 22,139,213 children vaccinated in 2028. In the elderly population in four growth markets (4GM: Australia, Japan, South Korea, and urban China) where vaccination in this age group is recommended, Theepidemiologists forecast an increase from 27,444,336 elderly vaccinated in 2018 to 39,002,217 elderly vaccinated in 2028. In the 5GM in 2018, the average pediatric vaccination rate was approximately 75%, while in the 4GM, the average elderly vaccination rate was approximately 45%. Additionally, Theepidemiologists forecast that the diagnosed incident cases of IPD in the 5GM will decrease from 2,038,634 cases in 2018 to 1,880,503 cases in 2028. In the future, continued efforts should focus on establishing national vaccine initiatives and goals and carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, increase vaccine awareness, and ultimately reduce IPD incidence worldwide.

Scope

- The Pneumococcal Vaccines Epidemiology report provide an overview of the risk factors and global trends of pneumococcal vaccines in the five growth markets (5GM: Australia, India, Japan, South Korea, and urban China).
- This report also includes a 10-year epidemiological forecast for the vaccinated pneumococcal population segmented by age (pediatric and elderly), and diagnosed incident cases of IPD segmented by age (04 years, 59 years, 1019 years, and by 10-year age groups up to 80 years and older). Pneumococcal vaccine dosing and age groups included within the forecast were dependent on the routine immunization requirements in each market and the availability of vaccination data. In addition, the epidemiology model corresponding to this report provides IPD diagnosed incident cases segmented into the top ten most common IPD serotypes by age (pediatric and elderly).
- The Pneumococcal Vaccines epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

Reasons to Buy

- The Pneumococcal Vaccines Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccines market.
- Quantify patient populations in the global pneumococcal vaccines market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for pneumococcal vaccine therapeutics in each of the markets covered.
- Understand magnitude of the pneumococcal vaccines population by dose and age.

2 Pneumococcal Vaccines: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Pediatric and Elderly Pneumococcal Vaccination Rates
3.3.2 Diagnosed Incidence of Invasive Pneumococcal Disease (Cases per 100,000 Population)
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.4.4 Pneumococcal Vaccination Rates in the Pediatric Population
3.4.5 Pneumococcal Vaccination Rates in the Elderly Population
3.4.6 Diagnosed Incident Cases of Invasive Pneumococcal Disease
3.5 Epidemiological Forecast for Pneumococcal Vaccines and Invasive Pneumococcal Disease (20182028)
3.5.1 Pneumococcal Vaccinated Pediatric Population
3.5.2 Pneumococcal Vaccinated Elderly Population
3.5.3 Diagnosed Incident Cases of IPD
3.5.4 Age-Specific Diagnosed Incident Cases of IPD
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

List Of Tables

Table 1: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
Table 2: Pediatric Pneumococcal Vaccination Rate Trends (%)
Table 3: Elderly Pneumococcal Vaccination Rate Trends (%)

List Of Figures

Figure 1: 5GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018 and 2028
Figure 2: 4GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018 and 2028
Figure 3: 4GM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 20082028
Figure 4: India, Diagnosed Incidence of IPD, Both Sexes, All Ages, 20082028
Figure 5: 5GM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
Figure 6: 4GM, Sources Used for the Pneumococcal Vaccinated Elderly Population
Figure 7: 5GM, Sources Used for the Diagnosed Incident Cases of IPD
Figure 8: 5GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
Figure 9: 4GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
Figure 10: 5GM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
Figure 11: Australia, Japan, and South Korea Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
Figure 12: India, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
Figure 13: Urban China, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available